Novo Nordisk Pharmatech closes distribution agreement for Russia and CIS countries
![Photo: Novo Nordisk Pharmatech/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13114470.ece/ALTERNATES/schema-16_9/doc7gjqf6lrmut1jif46hoh.jpg)
The ingredient-producing subsidiary of Novo Nordisk, Novo Nordisk Pharmatech, has entered an agreement with IMCoPharma for the distribution of the company's Quats (synthetic molecules) to the healthcare industry in Russia and countries in the Commonwealth of Independent States (CIS), according to Pharmaceutical Business review.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.